革兰染色指导初始抗生素治疗对呼吸机相关性肺炎患者临床反应的影响:GRACE-VAP随机临床试验
这项多中心、开放标签、非劣效性随机临床试验在日本12家三级转诊医院的ICU进行,纳入206例年龄≥15岁、改良临床肺部感染评分≥5分的VAP患者,随机接受革兰染色指导抗生素治疗或基于2016年IDSA/ATS指南的抗生素治疗。主要终点临床反应率在革兰染色指导组为76.7%(79例),指南组为71.8%(74例),风险差0.05(95%CI -0.07至0.17),非劣效性P<.001。革兰染色指导组显著减少抗假单胞菌药物(30.1%,95%CI 21.5%-39.9%,P<.001)和抗MRSA药物(38.8%,95%CI 29.4%-48.9%,P<.001)的使用。28天累积死亡率两组分别为13.6%(14例)和17.5%(18例)(P=.39),无显著差异;根据培养结果升级抗生素在革兰染色指导组为7例(6.8%),指南组为1例(1.0%)(P=.03)。结论提示革兰染色指导治疗非劣于指南治疗且减少广谱抗生素使用。
要点
- 在VAP患者中,革兰染色指导的初始抗生素治疗临床反应率为76.7%(79/103),指南组为71.8%(74/103),风险差0.05(95%CI -0.07至0.17),非劣效性P<.001。
- 革兰染色指导组较指南组显著减少抗假单胞菌药物使用(减少30.1%,95%CI 21.5%-39.9%,P<.001)和抗MRSA药物使用(减少38.8%,95%CI 29.4%-48.9%,P<.001)。
- 28天累积死亡率革兰染色指导组为13.6%(14例),指南组为17.5%(18例),组间无显著差异(P=.39)。
- 根据培养结果升级抗生素在革兰染色指导组为7例(6.8%),指南组为1例(1.0%),组间差异有统计学意义(P=.03)。
- ICU自由天数和 ventilator-free days 及不良事件两组间无显著差异。
适用人群与场景
- 年龄15岁或以上、诊断为VAP且改良临床肺部感染评分(modified Clinical Pulmonary Infection Score)为5分或以上的患者。
- 研究在日本12家三级转诊医院的ICU进行。
诊断标准与关键阈值
- VAP诊断结合改良临床肺部感染评分≥5分。
- 临床反应定义为:14天内完成抗生素治疗、基线影像学表现改善或无进展、肺炎症状和体征消退、未再次使用抗生素药物。
处置流程与药物剂量
- 革兰染色指导组:根据革兰染色结果选择初始抗生素治疗( restrictive 抗生素治疗)。
- 指南组:基于2016年美国感染病学会(IDSA)和美国胸科学会(ATS)VAP临床实践指南选择初始抗生素治疗(广谱抗生素治疗)。
- 根据培养结果升级抗生素:革兰染色指导组7例(6.8%),指南组1例(1.0%)。
研究设计与关键结果
- 研究类型:多中心、开放标签、非劣效性随机临床试验(GRACE-VAP),在日本12家三级转诊医院ICU进行,2018年4月1日至2020年5月31日,共随机206例患者(革兰染色指导组n=103,指南组n=103),中位年龄69岁(IQR 54-78),男性141例(68.4%)。
- 主要终点:临床反应率革兰染色指导组76.7%(79例) vs 指南组71.8%(74例),风险差0.05(95%CI -0.07至0.17),非劣效性P<.001。
- 次要终点:抗假单胞菌药物使用减少30.1%(95%CI 21.5%-39.9%,P<.001),抗MRSA药物使用减少38.8%(95%CI 29.4%-48.9%,P<.001),均为革兰染色指导组 vs 指南组。
- 28天累积死亡率:革兰染色指导组13.6%(14例) vs 指南组17.5%(18例),P=.39。
- 根据培养结果升级抗生素:革兰染色指导组7例(6.8%) vs 指南组1例(1.0%),P=.03。
- ICU自由天数、ventilator-free days 及不良事件两组间无显著差异。
证据类型、等级与局限
- 证据类型:多中心、开放标签、非劣效性随机临床试验。
- 非劣效性界值:20%。
- 主要分析基于符合方案集(per-protocol analysis population)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,革兰染色指导治疗非劣于指南指导治疗,并显著减少VAP患者广谱抗生素的使用。
- 作者认为,革兰染色可能有助于改善重症监护环境中的多重耐药菌问题。
指南或共识出处
- 2016年美国感染病学会(IDSA)和美国胸科学会(ATS)VAP临床实践指南。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Gram staining should provide immediate information for detecting causative pathogens. However, the effect of Gram staining on restricting the initial antibiotic choice has not been investigated in intensive care units (ICUs).
OBJECTIVE: To compare the clinical response to Gram stain-guided restrictive antibiotic therapy vs guideline-based broad-spectrum antibiotic treatment in patients with ventilator-associated pneumonia (VAP).
DESIGN, SETTING, AND PARTICIPANTS: This multicenter, open-label, noninferiority randomized clinical trial (Gram Stain-Guided Antibiotics Choice for VAP) was conducted in the ICUs of 12 tertiary referral hospitals in Japan from April 1, 2018, through May 31, 2020. Patients aged 15 years or older with a VAP diagnosis and a modified Clinical Pulmonary Infection Score of 5 or higher were included. The primary analysis was based on the per-protocol analysis population.
INTERVENTIONS: Patients were randomized to Gram stain-guided antibiotic therapy or guideline-based antibiotic therapy (based on the 2016 Infectious Disease Society of America and American Thoracic Society clinical practice guidelines for VAP).
MAIN OUTCOMES AND MEASURES: The primary outcome was the clinical response rate; clinical response was defined as completion of antibiotic therapy within 14 days, improvement or lack of progression of baseline radiographic findings, resolution of signs and symptoms of pneumonia, and lack of antibiotic agent readministration, with a noninferiority margin of 20%. Secondary outcomes were the proportions of antipseudomonal agents and anti-methicillin-resistant Staphylococcus aureus (MRSA) agents as initial antibiotic therapies; 28-day mortality, ICU-free days, ventilator-free days; and adverse events.
RESULTS: In total, 206 patients (median [IQR] age, 69 [54-78] years; 141 men [68.4%]) were randomized to the Gram stain-guided group (n = 103) or guideline-based group (n = 103). Clinical response occurred in 79 patients (76.7%) in the Gram stain-guided group and 74 patients (71.8%) in the guideline-based group (risk difference, 0.05; 95% CI, -0.07 to 0.17; P < .001 for noninferiority). Reduced use of antipseudomonal agents (30.1%; 95% CI, 21.5%-39.9%; P < .001) and anti-MRSA agents (38.8%; 95% CI, 29.4%-48.9%; P < .001) was observed in the Gram stain-guided group vs guideline-based group. The 28-day cumulative incidence of mortality was 13.6% (n = 14) in the Gram stain-guided group vs 17.5% (n = 18) in the guideline-based group (P = .39). Escalation of antibiotics according to culture results was performed in 7 patients (6.8%) in the Gram stain-guided group and 1 patient (1.0%) in the guideline-based group (P = .03). There were no significant differences between the groups in ICU-free days, ventilator-free days, and adverse events.
CONCLUSIONS AND RELEVANCE: Results of this trial showed that Gram stain-guided treatment was noninferior to guideline-based treatment and significantly reduced the use of broad-spectrum antibiotics in patients with VAP. Gram staining can potentially ameliorate the multidrug-resistant organisms in the critical care setting.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03506113.
参考来源
- Yoshimura J, Yamakawa K, Ohta Y, et al. Effect of Gram Stain-Guided Initial Antibiotic Therapy on Clinical Response in Patients With Ventilator-Associated Pneumonia: The GRACE-VAP Randomized Clinical Trial. JAMA Netw Open. 2022. PMID: 35394515. doi:10.1001/jamanetworkopen.2022.6136
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。